The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes
Authors' conclusion
A prasugrel based strategy was associated with a reduction in total MI events in comparison to a ticagrelor based strategy in patients with ACS undergoing invasive assessment. Total BARC type 3 to 5 bleeding events were comparable between the two groups.
Study context
- Population
- Patients with acute coronary syndromes (ACS) undergoing an invasive management strategy
- Participants
- 4,018 patients
- Comparison
- Prasugrel-based vs ticagrelor-based strategy
- Primary endpoint
- Total (first and recurrent) ischaemic events (myocardial infarction (MI) and stroke) and bleeding events (BARC type 3 to 5), on time-to-first event and total events analyses
Methodological detailspost-hoc analysis
- Post-hoc analysis
Primary result
As reported in the abstract
MI
Prasugrel vs TicagrelorHazard ratio (95% CI)
Time-to-first event
0.61(0.44–0.85)
Total events
0.62(0.45–0.86)
Safety
| Outcome | HR (CI) | |
|---|---|---|
| BARC type 3 to 5 bleedingPrasugrelvs TicagrelorTime-to-first event | 0.96 (0.75–1.25) | |
| BARC type 3 to 5 bleedingPrasugrelvs TicagrelorTotal events | 0.99 (0.76–1.31) | |
| 0.512Hazard ratio (log scale) |
Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding
- Comparable between the prasugrel and ticagrelor groups
Original publication
The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes. Eur Heart J Cardiovasc Pharmacother. Published 26 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →